Abstract
Introduction

Angiogenesis is one of the most crucial biological processes, which ensures the formation and physiological function of all organs and virtually all tissues
in the body [1] . However [3] [4] [5] . It is now quite evident that there is a plethora of pro-and anti-angiogenic factors that regulate the vasculature and are involved in the development and progression of neovascularization [6, 7] . Furthermore, the spatio-temporal balance of these pro-and anti-angiogenic factors is critical in determining whether vascular homeostasis or pathology occurs [8] . The collective evidence suggests that the vascular endothelial growth factor (VEGF) family is critical for angiogenesis [6, 7, 9] . Increasing VEGF in animal models promotes neovascularization and this can be reversed by neutralizing VEGF or its receptors [10] [11] [12] . VEGF is hypoxia-inducible and thus is dramatically up-regulated by the hypoxic environment associated with tumours and diabetic retinopathy [9, 12, 13] [11, 14, 15] [16] and thrombospondin [2] . When we think of receptor activation by these angiogenic factors we typically associate this with tyrosine kinase activation and downstream intracellular signalling driving a cascade of protein phosphorylation events [17] . However, it has long been recognized, and often dismissed, that full length receptors and receptor fragments are present within the cytosol and nucleus [18, 19] . It is now apparent that these translocated receptors provide an alternative signalling pathway, bind to transcription factors and associate with adherens junctions to regulate intercellular permeability [19] . Furthermore [5] .
. Moreover, treatment of patients with tumours or choroidal neovascularization with VEGF inhibitors such as Avastin or Lucentis significantly reduces the aberrant angiogenesis resulting in the regression of tumours and, in the case of choroidal neovascularization, vessel regression and improved vision
. However, many other factors including Delta/Notch, insulin-like growth factor-I (IGF-I), fibroblast growth factor (FGF), angiopoietin and placenta growth factor (PlGF) are also, given the correct tissue environment, strongly pro-angiogenic. It is also important to note that these factors are constitutively expressed in most tissues under physiological conditions and thus must play an important role in homeostasis. Their pro-angiogenic potential is regulated by a fine balance of anti-angiogenic factors including pigment epithelium-derived factor (PEDF), IGF-binding protein-3 (IGFBP-3)
This review will focus on the intracellular translocation of receptors in angiogenesis and will carefully examine the contribution of ␥-secretase and its active proteolytic component, presenilin, which plays a critical role in this process.
Regulated intramembrane proteolysis
Over the last decade regulated intramembrane proteolysis (RIP) has been revealed as a novel, but highly conserved mechanism in cell signalling (reviewed in [20] [21] [22] [23] (Fig. 1) . RIP is mediated by at least three distinct families of evolutionarily conserved intramembrane proteases, which cleave substrates usually within their transmembrane domains [22] : (1) the presenilin-type aspartyl proteases, including the presenilin-dependent ␥-secretase and the signal peptide peptidase (SPP) that cleave tyrosine kinase receptors and the HLA-E epitope [24] [25] [30, 31] . Nicastrin has recently been described as 'the gatekeeper of the ␥-secretase complex' [32] . The [30] ). There also appears to be allosteric modulation of ␥-secretase activity through binding of extrinsic factors to protein components in the complex (see Wolfe [30] [36] , that both PS and Pen-2 are transcriptionally regulated by cyclic AMP-response element binding protein (CREB) [37] and ubiquilin can regulate the post-transcriptional modification of PS, Pen-2 and nicastrin [38] .
Substrate cleavage
Presenilin-dependent regulated intramembrane proteolysis has been extensively studied in the context of Notch signalling. Cleavage of transmembrane proteins by presenilin leads to the generation of biologically [30] .
active protein fragments that signal at various locations within the cell including the nucleus and the adherens junctions (reviewed in [22] [26, 39, 40] . This cleavage of the ectodomain is typically carried out by proteases of the disintegrin and metalloprotease (ADAM) families, whose active site domain is located in the extracellular/luminal space [22, 41] [31] . Although, the mechanism by which this occurs has yet to be eluci- 
dated. The nuclear localization of membrane bound receptors appears to regulate gene expression either by (i) acting directly as a transcription factor (FGFR-1 acts as a transcription factor at the FGF-2 promoter) [54], (ii ) binding to and regulating the activity of transcription factors, (iii ) induction of early response and cell cycle genes [55] or (iv ) co-transport of other molecules into the nucleus (ErbB-1 has been reported to transport the tyrosine phosphorylated transcription factor STAT-3 from the cytosol into the nucleus) [56].
Presenilin-binding proteins
Role of ␥ ␥-secretase in angiogenesis
We and others have identified a potential role for ␥-secretase in vasculogenesis and angiogenesis [31, [67] [68] [69] [70] [71] [72] . Abnormal blood vessel development occurs in mice lacking presenilin-1 [68] . Presenilin-1 controls the growth and differentiation of endothelial progenitor cells [73] . [74] . [77] and Notch activation can regulate VEGF expression [80] . ␥-secretase is also critical for cell-autonomous notch signalling and regulates endothelial cell branching and proliferation during vascular tubulogenesis [69] .
An Ets domain is located on the PS promoter and Ets is known to be a key transcriptional regulator of vasculogenesis and angiogenesis
In [82] . Presenilin processing of ephrinB itself regulates EphB-induced Src phosphorylation and signalling [62] . It [84] . Thus Dll4, Notch and ␥-secretase all appear to play a critical role in VEGF-induced angiogenesis. 
Vascular endothelial growth factor receptor-1 (VEGFR-1)
Although VEGFR-2 has long been considered the major effector in VEGF-induced angiogenesis, there is a growing body of evidence that VEGFR-1 is a potent negative regulator of VEGFR-2 [12]. Mice expressing the VEGFR-1 extracellular and transmembrane domains but lacking the tyrosine kinase domain (VEGFR-1 TK(-) mice) develop an essentially normal vasculature [85], which suggests that the VEGFR-1 tyrosine kinase domain appears to be dispensable and that VEGFR-1 may signal via an alternative pathway or pathways. This process may also in part be dependent on the extracellular matrix since Nozaki and colleagues [86] observed that choroidal neovascularization induced by injury was increased by excess VEGF-A before injury but was suppressed by VEGF-A after injury. This antiangiogenic effect was mediated via VEGFR-1 activation that was silenced by secreted protein, acidic and rich in cysteine (SPARC). Thus, the mechanism by which VEGFR-1 supports angiogenesis is complex and likely involves several different mechanisms with different levels of specificity and controls. We have recently reported that ␥-secretase is expressed in retinal microvascular endothelial cells and is able to elicit regulated intramembrane proteolysis of VEGFR-1 as well as translocation and phosphorylation of the full length receptor [31]. The translocation of the cleaved intracellular domain of VEGFR-1 as well as full length VEGFR-1 acts as a potent negative regulator of VEGFR-2 driven neovascularization. Pigment epithelial-derived factor (PEDF), a potent anti-angiogenic factor, induces a greater than 8-fold increase in ␥-secretase activity in microvascular endothelial cells. This increase was not due to up-regulated gene expression but reflected mobilization of endogenous ␥-secretase constituents to the plasma membrane and an increase in the ratio of the active PS-1 C-terminal fragment (CTF) to inactive full length within 30 min. Once complex formation was complete, both PS-1 and nicastrin co-localized to membrane-bound VEGFR-1 but not VEGFR-2. From studies in other signalling systems, we believe that PS-1 is bound to nicastrin, which in turn binds to VEGFR1. We conclude from these observations that VEGFR-1 will have sequence domains for both nicastrin binding and PS-1 cleavage. Computational modelling studies show that the VEGFR-1 transmembrane domain is highly conserved and contains a valine site ('cvaatlfwllltlf'), which could serve as a substrate for PS-1. ␥-secretase induction in the presence of VEGF resulted in the appearance of an intracellular cleaved 80 kD C-terminal domain of VEGFR-1 within 1 hr after induction. Interestingly, even though we could induce the formation of an active ␥-secretase complex in the plasma membrane, VEGF binding to VEGFR-1 was essential before cleavage occured leading us to hypothesize that a change in VEGFR-1 conformation occurs which in turn exposes the conserved valine residue to PS-1. A challenging thought is that the 80 kD C-terminal fragments of VEGFR-1 released into the cytosol could act to inhibit VEGFR-
Insulin-like growth factor-I receptor (IGF-1R)
IGF-I is a potent pro-angiogenic factor which plays an important role in aberrant neovascularization
associated with diabetic retinopathy [6, 9] 
ErbB4
The Erb, or epidermal growth factor receptor, family of transmembrane tyrosine kinase receptors are implicated in a range of cellular responses including the regulation of angiogenesis both in vitro and in vivo [87] . One member of the EGF receptor family, ErbB-4 is known to undergo intramembrane proteolysis to generate an 80 kD intracellular domain which relocates to the nuclear compartment where it regulates gene transcription [88] . It has been elegantly demonstrated that, similar to the Notch system, upon binding to its ligand (heregulin, neuregulin, betacellulin) that the ErbB-4 ectodomain is cleaved by a metalloprotease and that ␥-secretase elicits a transmembrane cleavage thus releasing an intracellular domain [42, 89] . This regulated intramembrane proteolysis and the appearance of a cleaved fragment was blocked by inhibition of ␥-secretase or a dominant negative presenilin mutant [42] . The nuclear binding partners for the intracellular domain of ErbB-4 have yet to be fully elucidated. Arasada and Carpenter reported that the cleaved intracellular domain associates with and tyrosine phosphorylates MdM2, a protein that is predominantly localized to the nucleus and regulates p53 levels [63] . Omerovic and colleagues have identified the transcriptional transactivator YAP65 (yes-associated protein) as a binding partner for ErbB-4 using a yeast two hybrid screen [88] .
Interestingly, it appears that ␥-secretase-dependent processing of ␤-amyloid precursor protein (see APP section below) can itself regulate EGF receptor expression [90] suggesting a highly context-dependent regulation of the EGF receptor signalling system.
In addition to its more general role in regulating cell proliferation and differentiation it appears that ErbB-4 can play an important role in tumour angiogenesis [87, [91] [92] [93] [94] [95] [96] . Activation of ErbB-4 induces its phosphorylation and promotes HUVEC proliferation and migration. Signalling appears to involve the MAPK and PI3K/Akt pathways [93] . Interestingly, ErbB-4 colocalizes with ErbB-1 in HUVEC and aortic endothelial cells which opens the possibility that ErbB-4 may facilitate the entry of ErbB-1 into the nucleus [92] .
However, once in the nucleus ErbB-4 locates to the extra-nucleolar region while ErbB-1 is localized to the nucleoli. It is also clear that tumour angiogenesis is likely to be dependent on the differential regulation of distinct ErbB homo-and heterodimers. EGFR/ErbB-4, ErbB-2/ErbB-4 and ErbB-3/ErbB-4 can all induce VEGF expression although this induction is not as great as for EGFR/ErbB-2 and ErbB-2/ErbB-3 [87]. Stimulation of HUVEC with recombinant neuregulin-␤ (an ErbB-3/ErbB-4 ligand) induces marked in vitro and in vivo angiogenic
responses which are independent of VEGF [95] . It has also been shown that ligand binding induces ErbB-3 and ErbB-4 heterdimerization with ErbB-2 which increases secretion of VEGF from breast cancer cells via a p38 MAPK [96] . However, neuregulin-2, a ligand for EGF receptors including ErbB-4, has an inhibitory activity on angiogenesis [94] . While [101] . [29] . However, it is now becoming evident that amyloid may be associated with pathological angiogenesis, especially that associated with diabetic retinopathy and age-related macular degeneration (AMD) in the eye. Amyloid is present in Drusen which are a hallmark of AMD [102, 103] [67] . It is likely that APP/amyloid also contributes to angiogenesis outside of the eye since amyloid-␤ is associated with vasculogenesis in the brain [107] , amyloid-␤ is highly expressed in the endothelium of newly forming vessels and ␥-secretase-dependent processing of APP can regulate tyrosine kinase receptor expression [90] .
Amyloid precursor protein (APP)
␥-secretase is traditionally recognized for its contribution to the proteolytic cleavage of amyloid precursor protein (APP) to the amyloid-␤ peptide which is present in senile plaques in the brain
Other substrates
As elegantly highlighted in a recent review by Parks and Curtis at least 25 ␥-secretase substrates have been identified to date [46] . These show tremendous diversity and include growth hormone receptor [108] , syndecan-3 [109] , tyrosinase [110] , CD44 [111] and HLA-A2 [112] .
The cleaved intracellular domain can regulate transcriptional activity (CD44), protein localization (tyrosinase, syndecan-3), represent degradation (HLA-A2) or function remains unclear (growth hormone receptor). It is almost a certainty that addi-
tional ␥-secretase substrates will be discovered in the future and that new intracellular pathways for regulation of cellular function will be identified.
␥ ␥-Secretase as a therapeutic target
Targetting ␥-secretase in the prevention of aberrant angiogenesis is now a real possibility. However, given the ubiquitous expression and diverse substrates for ␥-secretase it will be important to develop ␥-secretase substrate-specific compounds. Furthermore, in some situations ␥-secretase inhibition can prevent angiogenesis while in the case of VEGFR-1 for example it is ␥-secretase up-regulation which blocks angiogenesis [31] .
Exogenous negative regulation of ␥-secretase activity has been extensively studied within the Alzheimers field with a view to therapeutic intervention in the formation of senile plaque [29, 30, 113] [114] .
Although, the concept of ␥-secretase inhibitors is attractive, it appears that in some facets of angiogenesis an increase in ␥-secretase activity acts as a negative regulator of angiogenesis [31] . We have recently shown that PEDF, a non-classic serpin, is a potent up-regulator of ␥-secretase activity and acts by promoting translocation of the components of the constituents of the ␥-secretase complex to the cell membrane. In addition, an increase in ␥-secretase activity has also been reported following activation of the ␤2-adrenergic receptor [115] and following application of TO-901317, a liver X receptor agonist [116] . Given 
